| scholarly article | Q13442814 |
| P2093 | author name string | Gregory V Stark | |
| Lisa N Henning | |||
| Natalya V Serbina | |||
| Sarah Carpenter | |||
| P2860 | cites work | Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings | Q24718884 |
| Cellular and physiological effects of anthrax exotoxin and its relevance to disease | Q27010363 | ||
| Raxibacumab for the treatment of inhalational anthrax | Q28251284 | ||
| Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity | Q28390214 | ||
| Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax | Q28392283 | ||
| Monoclonal antibody therapies against anthrax | Q28393072 | ||
| A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge | Q28398021 | ||
| Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration "Animal Rule". | Q30201937 | ||
| Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge | Q30540217 | ||
| Threats in bioterrorism. I: CDC category A agents | Q34743491 | ||
| Antibodies against anthrax: mechanisms of action and clinical applications | Q35610439 | ||
| Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax | Q35652068 | ||
| Natural cutaneous anthrax infection, but not vaccination, induces a CD4(+) T cell response involving diverse cytokines | Q35726627 | ||
| Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax | Q36155940 | ||
| Contribution of toxins to the pathogenesis of inhalational anthrax | Q36708397 | ||
| Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis | Q36970295 | ||
| Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax | Q37287801 | ||
| Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis | Q37336235 | ||
| Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule | Q37594165 | ||
| Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident | Q38384713 | ||
| Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection | Q38749263 | ||
| Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated | Q40213025 | ||
| Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans | Q40838287 | ||
| Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques | Q41755913 | ||
| Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model | Q41869569 | ||
| Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults | Q42735019 | ||
| The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. | Q43662258 | ||
| Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin | Q44389292 | ||
| Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax | Q45043237 | ||
| A cautionary note on exact unconditional inference for a difference between two independent binomial proportions | Q50493198 | ||
| Postexposure prophylaxis against experimental inhalation anthrax | Q64051299 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | New Zealand | Q664 |
| antibiotic | Q12187 | ||
| Bacillus anthracis | Q614156 | ||
| P577 | publication date | 2017-11-13 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen | |
| P478 | volume | 62 |
Search more.